EGFR and non-small cell lung carcinoma: In previous prospective phase III clinical trials assessing the efficacy of first-line EGFR-TKIs in the treatment of NSCLC, only 27 cases of LSCC patients with EGFR mutation were identified in six clinical trials, which were further randomized into two groups.177–182 This limited number of LSCC cases makes it hard to assess the benefits of EGFR-TKIs for EGFR-mutated LSCC in prospective studies.